首页> 外文期刊>Sage Open Medicine >Evolving ethics, policy and reimbursement issues of vascularized composite allotransplantation: Symposium summary
【24h】

Evolving ethics, policy and reimbursement issues of vascularized composite allotransplantation: Symposium summary

机译:血管化复合分征的不断发展的伦理,政策和报销问题:研讨会摘要

获取原文
           

摘要

In this article, we present a report from a national meeting titled, “Evolving Issues of Vascularized Composite Allotransplantation—A Symposium on Ethics, Policy, and Reimbursement Issues,” which convened in September 2017. We discuss the maturation of vascularized composite allotransplantation from an emerging technology to becoming an extension of clinical practice for select patients with complex reconstructive needs. Viewpoints and action items were presented by and discussed among the 70+ clinicians, researchers, policymakers, ethicists, healthcare administrators, and third-party payers who attended the symposium with the goals of implementing a collaborative roadmap for vascularized composite allotransplantation growth, evaluation, and sustainability by establishing a unified plan to help address concerns of the public, policymakers, and healthcare finance. We review the current status of vascularized composite allotransplantation in clinical practice and summarize symposium discussions regarding ethical considerations, reimbursement, payer strategies, and standardization of data collection.
机译:在本文中,我们在2017年9月召开的“血管化综合分征问题 - 伦理学,政策和报销问题讨论会上演变问题 - 血管化综合和报销问题研讨会”的报告。我们讨论了血管化复合分征的成熟新兴技术成为选择复杂重建需求患者的临床实践的延伸。在70多名临床医生,研究人员,政策制定者,伦理学家,医疗管理人员和第三方付款人中介绍了并讨论了就血管化综合分征性增长,评估和综合性分征的目标的参加人员参加研讨会通过建立统一的计划来帮助解决公众,政策制定者和医疗保健金融的担忧的统一计划。我们审查了临床实践中血管化复合分征的现状,总结了关于道德考虑,报销,付款人策略和数据收集标准化的研讨会讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号